Confirmed via cytology, sEVs from the plasma of glioma patients exhibited enrichment of ephrin type-A receptor 2 (14.7-fold), tenascin C (22.7-fold), and glial fibrillary acidic protein (8.4-fold) [62]. The gene discussed is EPHA2; the disease is central nervous system cancer.